Adriforant hydrochloride (PF-3893787 hydrochloride) is a potent and selective histamine H4 receptor antagonist with high affinity (Ki = 2.4 nM for H4R binding; Ki = 1.56 nM for H4R functional antagonism), developed for the treatment of inflammatory and allergic conditions, including eosinophil-mediated disorders. It effectively inhibits actin polymerization in human eosinophils (IC50 = 1.16 nM) and blocks histamine-induced shape change in whole blood assays at low nanomolar concentrations, supporting its potential therapeutic application in diseases driven by H4 receptor activation.